Helixgate

Helixgate

Endpoints News

Maze meets own expectations in Phase 2 kidney disease trial in the same arena as Vertex

Published

on

Maze Therapeutics unveiled positive mid-stage data for its genetic kidney disease drug that could spell major competition for Vertex Pharmaceuticals’ program that has the same target.

Maze’s candidate, codenamed MZE829, produced an average 35.6% reduction …

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Endpoints News

A week of bolt-on deals; Wave crashes on obesity data; Sanofi partners with TCE startup; and more

Published

on

Welcome back to Endpoints Weekly! Our team tracked a handful of deals announced this week as the first quarter comes to a close. Check below for a summary of those moves, including Merck’s $6.7 billion …

Continue Reading

Endpoints News

Otsuka buys Transcend Therapeutics for $700M upfront

Published

on

Otsuka is buying neuropsychiatric drugmaker Transcend Therapeutics in a deal worth roughly $1.2 billion, further bolstering a class of drugs that are supposed to provide the therapeutic benefits of psychedelics without the trip.

As part …

Continue Reading

Endpoints News

CHMP recommends subcutaneous form of Sanofi’s Sarclisa and four new drugs

Published

on

The European Medicines Agency’s human medicines committee has recommended the approval of four new drugs and a new form of Sanofi’s multiple myeloma drug.

CHMP gives its opinions on drug approvals and label expansions to …

Continue Reading
Advertisement

Trending